Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Generex and NSABP to manage Phase II clinical trial of keytruda

Pembrolizumab will be trailed in combination with the AE37 peptide vaccine for metastatic triple negative breast cancer. Credit: Bakerstmd.

Go Top